Key Updates in WHO TB Treatment Guidelines Compared to NTEP
The WHO 2020 guidelines introduce all-oral shorter regimens for drug-resistant TB, most notably replacing injectable agents with bedaquiline in 9-11 month MDR/RR-TB regimens and recommending the ultra-short 6-9 month BPaL regimen for fluoroquinolone-resistant cases—representing a fundamental shift from NTEP's traditional longer, injectable-containing protocols. 1
Major Differences in Drug-Resistant TB Treatment
Shorter All-Oral Bedaquiline Regimen (9-11 months)
WHO now conditionally recommends a 9-12 month all-oral regimen for MDR/RR-TB patients without fluoroquinolone resistance, replacing injectable agents with bedaquiline 1. This regimen includes:
- Intensive phase (4-6 months): Bedaquiline (6 months total), levofloxacin/moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine
- Continuation phase (5 months): Levofloxacin/moxifloxacin, clofazimine, ethambutol, and pyrazinamide
This contrasts with NTEP's traditional approach that relied heavily on injectable agents (kanamycin, amikacin) for 6-9 months, which carried significant ototoxicity risks and required daily injections.
Ultra-Short BPaL Regimen (6-9 months)
For MDR-TB with additional fluoroquinolone resistance, WHO conditionally recommends the BPaL regimen (bedaquiline, pretomanid, linezolid) for 6-9 months under operational research conditions 1. This represents a dramatic reduction from the 18-20 month regimens traditionally used by NTEP for extensively drug-resistant cases.
Safety Profile Updates
Bedaquiline Use Beyond 6 Months
WHO 2020 guidelines conclude no major safety concerns exist for:
- Bedaquiline use >6 months duration
- Concurrent use of bedaquiline and delamanid
- Bedaquiline during pregnancy (though associated with low birthweight, no other significant adverse infant or maternal outcomes were noted) 1
These statements provide greater flexibility than previous restrictions, though formal recommendations were not made.
Drug-Susceptible TB Considerations
While the provided WHO guidelines focus on drug-resistant TB, recent updates 2 recommend 4-month regimens for drug-susceptible pulmonary TB in adults and children with nonsevere disease—potentially shorter than NTEP's standard 6-month regimen, though NTEP has been transitioning from intermittent to daily dosing 3.
Critical Implementation Differences
Eligibility Criteria for Shorter Regimens
WHO specifies the shorter bedaquiline regimen is appropriate when:
- Confirmed MDR/RR-TB with rifampicin resistance
- Fluoroquinolone resistance excluded (requires rapid molecular testing)
- <1 month prior exposure to second-line drugs
- No extensive bilateral cavitary disease or severe extrapulmonary TB 1
NTEP protocols have historically been less restrictive about disease extent for shorter regimens.
Injectable Agent Positioning
WHO relegates aminoglycosides (amikacin, streptomycin) to use only when drug susceptibility is confirmed and high-quality audiometry monitoring is available 1. Streptomycin is considered only if amikacin is unavailable or resistance is documented. This represents a major de-emphasis compared to NTEP's historical reliance on injectables as core second-line agents.
Evidence Quality Caveat
Both new WHO recommendations carry conditional grading with very low certainty evidence 1. The guidelines explicitly acknowledge the shortage of high-quality randomized controlled trial data, particularly for the bedaquiline-containing shorter regimen. Implementation requires careful patient selection and monitoring, especially in programmatic settings where NTEP operates.
Practical Implications for India
The shift to all-oral regimens addresses major operational challenges in NTEP:
- Eliminates need for daily injectable administration infrastructure
- Reduces ototoxicity burden (critical given India's high MDR-TB caseload)
- Improves treatment adherence through oral administration
- Shortens treatment duration, reducing loss to follow-up
However, NTEP must ensure rapid molecular DST capacity for fluoroquinolone resistance detection and bedaquiline availability before widespread implementation of these WHO recommendations.